Oct. 7, 2013
/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that
, Ph.D., Sangamo's senior director of corporate communications, will give a company presentation at the 3
Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held
October 14-16, 2013
La Jolla, CA.
Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held
&15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry.
The following are specific details regarding Sangamo's presentation at the conference:
Regen Med Partnering Forum – 2013 Stem Cell Meeting on the Mesa
October 14, 2013
Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road,
La Jolla, CA
A live video webcast of all company presentations will be available at:
and will also be published on ARM's website shortly after the event.
for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors and media should contact
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic
for the treatment of HIV/AIDS. As part of its recent acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at
is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.